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1. Introduction 
1.1 Thrombomodulin Protein C System 
Thrombomodulin (TM), CD141 or BDCA-3, is an integral membrane protein 
expressed mostly on the surface of endothelial cells. TM has a key function in 
regulation of the coagulation system, not only by inhibiting thrombin, but also by 
activation of protein C (PC). In complex with TM thrombin can activate PC zymogen 
and produce activated PC (aPC), PC activation can be enhanced by approximately 
20 folds when binding to Endothelial protein C receptor (EPCR). aPC then provides a 
feedback inhibition by inactivating factor Va and VIIIa. Besides providing a negative 
feedback mechanism of coagulation activation, aPC mediates anti-inflammatory and 
anti-apoptotic activity via protease activated receptor-1 (PAR-1, Figure 1.1). 
 
                                                     de Wouwer, M. V. ATVB 2004 
Figure 1.1 Overview of thrombomodulin Protein C System. 
A simplified model is presented to describe the possible functions of TM, PC/aPC, 
and EPCR. Thrombin (IIa) is primarily generated locally by the tissue factor pathway 
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(e.g. induced by endotoxin or following mechanical injury of the endothelial cell layer). 
Adequate vasculoprotection to prevent fulminant tissue damage can be provided by 
aPC, which prevents further thrombin generation, but also provides cytoprotection via 
receptor dependent mechanisms. The latter is typically achieved when aPC – in the 
presence of the co-receptor EPCR (endothelial protein C receptor) – binds to and 
proteolytically activates PAR-1 (protease activated receptor-1). This results, for 
example, in inhibition of MAPK signaling and NF-kB activation, which interferes with 
leukocyte activation/adhesion and cytokine production. The net effect is endothelial 
cell protection (1).  
 
1.2 Structure and function of thrombomodulin 
TM was first identified and isolated by Esmon and Owen owing to its anticoagulant 
properties (2; 3) more than 25 years ago. Since then, steady progress has been 
made in elucidating the molecular mechanisms by which this single molecule 
regulates coagulation, inflammation, fibrinolysis and cellular proliferation. Although 
originally described as vascular endothelial cell receptor, TM has since been detected 
in variety of cells and tissue in adults and during development, including astrocytes, 
keratinocytes, mesothelial cells, neutrophils, monocytes and platelets. Consequently, 
it is no surprise that it has functions beyond coagulation (1; 4). 
 
1.2.1 Molecular structure of thrombomodulin 
TM is a type 1 transmembrane glycoprotein (557 AA (amino acids)) consisting of 6 
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functional domains. A large, 154 AA N-terminal lectin like domain is followed by a 
hydrophobic domain, 6 EGF-like domains, a Serine/Threonine rich domain, a single 
transmembrane domain, and a short intracellular domain (Figure 1.2) (4). 
 
 
 
Esmon C.T., Nat Med 2005 
Figure 1.2 Structure and function of Thrombomodulin. 
TM is a multi-domain proteoglycan found primarily on the endothelium. Addition, TM 
can bind thrombin, the terminal enzyme of the blood clotting cascade. EGF like 
repeats 4, 5, and 6 (EGF 4 to 6) have been studied in detail by several groups and are 
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essential in activation of protein C (Figure 1.2). EGF 3 to 6 are important for activation 
of thrombin activatable fibrinolysis inhibitor (TAFI) by thrombin (5). When TAFI is 
activated by proteolysis at residue Arginine 92 by the thrombin/thrombomodulin 
complex, it exhibits carboxypeptidase activity. Activated TAFI reduces fibrinolysis by 
removing the fibrin C-terminal residues that are important for the binding and 
activation of plasminogen(6; 7). Additional antifibrynolytic activity is supported by the 
EGF-like repeats of TM, because they also accelerate thrombin-mediated conversion 
of single-chain urokinase-type plasminogen activator (scu-PA) to thrombin-cleaved 
2-chain urokinase-type plasminogen activator (tcu-PA/T), thereby interfering with the 
generation of plasmin(8; 9). The major functions of TM are described in details below. 
 
1.2.2 Activated Protein C 
Physiological proteolytic activation of protein C (PC) by thrombin occurs on the 
surface of the endothelial cell and involves the two membrane receptors, 
thrombomodulin (TM) and endothelial protein C receptor (EPCR, Figure 1.3)(1). 
Activation of PC by the TM-thrombin complex is augmented by localization of protein 
C on the endothelial surface by its binding to EPCR (Figure 1.3) (10) . 
 
Activation of the blood coagulation system is triggered by various stimuli, which all 
lead to exposure of TF and direct contact of TF with soluble coagulation zymogens 
within the blood. TF then interacts with small amounts of fVIIa, activating factor X, 
which results in a short-lived generation of small thrombin levels. If the initial thrombin  
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Esmon C.T., Chest 2003 
 
Figure 1.3 Inactivation of factor Va and VIIIa by aPC generated on endothelium. TM, thrombomodulin; PC, 
protein C; APC: activated protein C; Pro, Prothrombin; T, thrombin; S, protein S; EPCR, endothelial 
protein C receptor, aPC, activated protein C; X, factor X; Xa, activated factor X; IXa, activated factor IX; V, 
factor V; Va, activated factor V; Vi, inactivated factor V; VIIIa, activated factor VIII; VIIIi, inactivated factor 
VIII;.  
 
generated is not effectively inhibited it will initiated a feedback amplification, activating 
factor XI as well as the cofactors fVIII an fV. This mechanism allows for sustained and 
sufficient thrombin generation to occur. Thrombin activates fibrinogen, resulting in 
fibrin formation, and activates platelets, resulting in thrombus formation, which is 
required for vascular healing, but my also result in vascular thrombosis in the case of 
uncontrolled thrombin generation. One important feedback mechanism to prevent the 
latter is provided by thrombin binding to thrombomodulin (TM). When complexed with 
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TM thrombin acquires a new substrate specificity, becoming a potent activator of 
protein C. Once aPC dissociates from EPCR, it binds to protein S, and this complex 
then inactivates factors Va and VIIIa. In the case of factor VIIIa, the process is 
enhanced further by factor V (in regard to factor VIIIa inactivation), high density 
lipoprotein, anionic phospholipids (e.g. phosphotidylserine, cardiolipin), and 
glycosphingolipids (e.g. glucosylceramide) (11). 
 
aPC is a serine protease with well-characterized anticoagulant activity. Studies have 
demonstrated that aPC reduces organ damage and improves survival in animal 
model of sepsis (12) and in humans with severe sepsis (13), prevents apoptosis in 
cortical neurons and protects brain from ischemic injury (14). It also prevents 
p53-dependent apoptosis in hypoxic endothelium in vitro and in vivo (15).  And most 
of the above mentioned cytoprotective effects are protease activated receptors 
dependent (12-16).   
 
1.2.3 Protease activated receptors 
Protease activated receptors (PARs) belong to the member of the 7 transmembrane 
domain G-protein coupled receptor family, and their activation requires cleavage at a 
specific site within their extracellular amino terminus (Figure 1.2). This cleavage 
produces a new aminoterminus, which then acts as a tethered ligand for the receptor. 
PAR-1 was first discovered as a human platelet thrombin receptor (17) and today four 
homologous PARs (PAR-1, 2, 3, and 4) are known in man and other species (18; 19). 
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PARs are activated by the action of serine proteases such as thrombin (acts on PARs 
1, 3 and 4) and trypsin (PAR-2) (7). The tissue and cell specific expression of PARs, 
different activating proteases, and various co-receptors which have been discovered 
over the last years allow differential effects, surprisingly different concentration of 
thrombin has be shown to have not only disruptive but aslo protective effect on 
endothelial cells (20), we were also able to show low-dose thrombin (50pM) 
prevented, whereas high-dose thrombin (20nM) aggravated, glucose-induced 
apoptosis in cultured podocytes (21), this effect is PAR-3 dependent(unpublished 
data).   
                                        
In 2007 we found out that within the renal glomeruli, aPC preserves endothelial cells 
via a PAR-1 and endothelial protein C receptor-dependent mechanism (16). 
Conversely, the signaling mechanism through which aPC protects podocytes remains 
unknown. While exploring the latter, we identified a novel aPC/PAR-dependent 
cytoprotective signaling mechanism. In podocytes, aPC inhibits apoptosis through 
proteolytic activation of PAR-3 independent of EPCR. PAR-3 is not signaling 
competent itself as it requires aPC-induced heterodimerization with PAR-2 (human 
podocytes) or PAR-1 (mouse podocytes). This cytoprotective signaling mechanism 
depends on caveolin-1 dephosphorylation (Figure 1.4). This novel, aPC-mediated 
interaction of PARs demonstrates the plasticity and cell-specificity of cytoprotective 
aPC signaling (22). The evidence of specific, dynamic signaling complexes 
underlying aPC-mediated cytoprotection may allow the design of cell type specific 
targeted therapies. 
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 Figure 1.4 Schematic representation of differential signaling of aPC in podocytes and endothelial cells.  
                           Madhusudhan T,  Wang H, Isermann B et al Blood 2012 
aPC’s receptor dependent, cytoprotective effects result in (1) alteration of gene 
expression profile; (2) anti-inflammatory activities; (3) anti-apoptotic activities; and (4) 
endothelial barrier stabilization. Although potentially inter related, each of these 
activities of aPC is distinct and may or may not involve same intracellular 
mechanisms with their particular characteristics, depending on a cell’s receptor profile 
and on a particular cell’s location. 
  
1.2.4 Lectin like domain of thrombomodulin 
In addition to TM´s activated PC-dependent cytoprotection, the function of its 
lectin-like domain has been broadly investigated. At the N-terminus of the molecule 
there is a 154-amino acid residue module with homology to other C-type lectins (23; 
24). Electron microscopy and computer models indicate that the lectin-like domain of 
TM is globular and situated furthest away from the plasma membrane, because of its 
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unique structure and location it might effectively and easily interact with other 
molecules (25; 26). Study shows that the lectin-like domain confers protection from 
neutrophil-mediated tissue damage by suppressing adhesion molecule expression 
via nuclear factor kappaB and mitogen-activated protein kinase pathways (27). 
Abeyama et al. show that the lectin-like domain binds the proinflammatory molecule. 
HMGB1 blocks cell signaling mediated by RAGE and possibly other receptors (28). 
The lectin-like domain can also dampen cell activation signals by dampening the 
MAPK and NF-κB pathways, presumably through interaction with an as yet 
unidentified receptor. Another group in Japan shows the lectin-like domain dependent 
effects may be related to scavenging of HMGB-1, a proinflammatory mediator and 
inhibition of apoptosis (Figure 1.2) (29).  
 
1.2.5 Thrombomodulin and complement  
Besides the above mentioned diverse function, TM plays also very important roles in 
regulating complement system. Via its epidermal growth factor-like repeats, TM 
suppresses thrombin (IIa)-mediated activation of C5 to C5a. TM also accelerates 
thrombin-mediated activation of TAFI (thrombin activatable fibrinolysis inhibitor), and 
activated TAFI (TAFIa) in turn cleaves and inhibits C3a and C5a (30). In the 
complement alternative pathway TM binds directly to complement factor H (CFH) and 
C3b, and facilitates the cofactor activities of CFH and of C4bBP (C4b-binding protein) 
for CFI (complement factor I)-mediated inactivation of C3b (30). TM also limits the 
complement activating properties of CFB/CFD (complement factors B and D) (31; 32). 
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The binding site(s) on TM for CFH, C3b and C4b are not known. In the classical/lectin 
pathway TM is a receptor for C4b and augments the cofactor activity of C4bBP in 
CFI-mediated inactivation of C4b (Figure 1.4) (30) 
 
Figure 1.5 Model representing mechanisms by which TM negatively regulates complement.  
Taken together each of these diverse functions is mediated by different domains of 
TM. Especially, the lectin-like domain of TM can mediates anti-inflammatory and 
cytoprotective effects via different pathways. Van de Wouwer et al shows that the 
lectin like domain can interfere with complement activation and protect against 
arthritis (33; 34). The relevance of TM-dependent complement inhibition in chronic 
vascular diseases, such as diabetic nephropathy, remains elusive.  
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1.3 Diabetic nephropathy 
Diabetic nephropathy is the most frequent cause of end-stage renal failure in 
industrialized countries (35; 36). In addition to impairment of renal function, the 
manifestation of diabetic nephropathy is associated with a poor prognosis for affected 
patients, increasing the risk for cardiovascular complications and death.  
 
 
Figure 1.6 Schematic representation of glomerular filtration barrier. Overview (left) and detailed view 
(corresponding to the boxed area on the left) of the glomerular filtration barrier. Fenestrated endothelial cells, 
facing the capillary lumen, form the inner aspect, while podocytes and their foot processes form the outer aspect 
of the glomerular filtration barrier. Both cell layers are separated by a basal lamina (also known as the glomerular 
basement membrane). Spaces in between the foot processes form the filtration slit. (37).  
 
Despite significant progress in our understanding of diabetic nephropathy, the 
translational efforts fell short their expectations (16). Thus, the delineation of new 
therapeutic approaches based on novel pathophysiological insights is needed.  
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1.3.1 Endothelial dysfunction in diabetic nephropathy   
Diabetic vascular disease is a major clinical problem thought to be causative for 
diabetes related complications such as arteriosclerosis and nephropathy. Chronic 
exposure to hyperglycemia induces toxic metabolites like reactive oxygen species and 
advanced glycation end products in various cell types and this is thought to contribute 
to diabetic structural vascular alterations (38; 39). Studies in humans indicate that 
markers of endothelial dysfunction are associated with microangiopathy in type 1 and 
2 diabetes. Since the endothelium is a key component of the glomerular filtration 
barrier (Figure 1.6), the association of markers of endothelial dysfunction with diabetic 
complications is particularly true in patients with type 1 diabetes who have either early 
(microalbuminuria) or late (macroalbuminuria) nephropathy. In these patients 
increased blood levels of von Willebrand factor (vWF), adhesion molecules (ICAM, 
VCAM), selectins, thrombomodulin, PAI-1, type IV collagen and tPA are considered 
markers of endothelial dysfunction (40; 41). In addition, circulating annexin V-positive 
endothelial microparticles are associated with vascular dysfunction in patients with 
end stage renal failure indicating endothelial cell apoptosis (42).  
 
In vitro studies have demonstrated that hyperglycemia increases expression of 
pro-inflammatory and pro-apoptotic proteins that have been linked with endothelial 
dysfunction and apoptosis (43; 44). The presence of these markers of EC dysfunction 
before the development of the disease suggests endothelial dysfunction precedes 
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diabetes induced end organ failure (16; 40; 41). However the mechanism underlying 
endothelial cell dysfunction and apoptosis and their pathogenic role in development of 
diabetic nephropathy is not well understood.  
 
1.3.2 The role of podocyte in diabetic nephropathy 
The filtration barrier is a dynamic structure, in which all three components (endothelial 
cells, GBM and podocytes) play an integral functional role (Figure 1.6). There have 
been several studies of glomerular ultrastructure in patients with type 1 diabetes 
spanning the spectrum from normoalbuminuria through microalbuminuria to overt 
nephropathy. Using light microscopy, comparisons of renal ultrastructural changes in 
microalbuminuric patients and healthy controls have focused on basement 
membrane thickening and matrix/glomerular volume fraction. In some studies, 
microalbuminuric patients were shown to have significantly increased glomerular 
basement membrane thickness and matrix/glomerular volume fraction when 
compared with normoalbuminuric patients(45-47). Using electron microscopy, 
alterations in podocytes have been described even in normoalbuminuric patients 
(Tab. 1.1). In a mixed group of type 1 diabetic patients with microalbuminuria and 
overt nephropathy, the first observations of an altered glomerular epithelial cell 
structure, like process width, filtration slit length density and total filtration slit length, 
were reported in 1987 (48). This showed increased foot process width in patients with 
either microalbuminuria or overt nephropathy compared with control subjects. 
Widening of filtration slits did not correlate with increases in albuminuria, but a 
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decrease in filtration slit width was associated with a decrease in glomerular filtration 
rate (49).  A subsequent study by Steffes in 2001 found that podocyte density did not 
change with duration of diabetes or severity of diabetic nephropathy (49). However, 
decrease in podocyte number was found in patients with type 1 diabetes compared 
with controls, even in those with a relatively short duration of diabetes.  
The main findings of studies examining podocyte dysfunction in type 2 diabetes are 
summarized in Table 1.2. The first two studies of podocyte ultrastructure in type 2 
diabetes were performed in Pima Indians. Thus, these results, which may be 
confounded by the specific genetic background, cannot necessarily be extended to 
other groups. Anyway, in the first study, 51 patients with a range of albumin excretion 
rates from normo- to macroalbuminuria were studied (50). Microalbuminuria could not 
be distinguished from normoalbuminuria on structural grounds. Broadening of foot 
processes was associated with enlarged glomeruli and a decrease in podocyte 
density predicted progression of albumin excretion rate over 4 year (51). 
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                              Table 1.1 Ultrastructure of Podocytes in type 1 Diabetes 
 
 
 
Study Subjects Stage of nephropathy         Findings  
Ellis (1987)  28 diabetic 
28 nondiabetic 
15 N 
5 micro 
1. FPW in micro equal to FPW in N 
2. ↑ FPW in micro patients c/w control subjects 
  8 overt 3. ↑ FPW with overt DN 
Bjorn (1995) 27 diabetic 
11 nondiabetic 
9 N 
9 micro 
9 overt 
1. Overall trend to ↑ FPW with ↑ AER 
2. Widening of filtration slits does not explain ↑ AER 
3. Filtration slit width ↓ as GFR ↓ 
Berg (1998)  36 diabetic 36 N 1. Negative correlation between FPW and AER 
 (adolescents)     (8 transient micro at 
     time of biopsy) 
2. Negative correlation between filtration slit length density and AER 
   3. ↑ FPW suggests glomeruli are enlarged and/or exposed 
to ↑ intraglomerular pressure 
Steffes (2001)  46 diabetic Varied (AER data not shown) 1. Podocyte density did not change with duration of diabetes or severity of DN 
 
 
White (2002) 
Esprit Study 
36 nondiabetic 
 
 
50 diabetic 
(all normotensive) 
10 nondiabetic 
 
 
 
    32 Micro 
    18 overt 
     Enal april vs nifedipine 
     vs placebo 
  2.  Podocyte number in diabetes c/w controls, even in short duration diabetes 
  
 
 1. Overall no significant ↓ in podocyte number in normotensive patients with  
    raised AER 
 2.In subgroup with overt DN: podocyte number correlated negatively with ↑ AER 
 3.In placebo-treated patients: decrease in podocyte density over 3 yr correlated  
   with final AER 
 4.Association between podocyte loss and AER may be response to, cause of,or 
   concomitant with, 
        
DN, diabetic nephropathy; N, normoalbuminuria; micro, microalbuminuria; FPW, foot process width; AER, albumin excretion rate; c/w, compared with 
                                                                                      from: George Jerums, Podocytes and Diabetic Nephropathy, 2006
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                                                                   Table 1.2 Ultrastructure of Podocytes in type 2 Diabetes 
 
 
 
Study Subjects Stage of nephropathy Findings  
Pagtalunan (1997)  
 
51 diabetic (Pimas) 
Eight nondiabetic 
10 N-early 
12 N-late 
17 micro 
1. Micro could not be distinguished from N on structural grounds 
2. Broadening of foot processes associated with large glomeruli 
and ↓ podocyte number in overt DN 
  12 overt 3. Podocyte loss contributes to progression of DN 
Meyer (1999)  16 diabetic (Pimas) micro 1. Podocyte density predicts AER ↑ over 4 yr 
2. Podocytes important in development and progression of DN 
Dalla Vestra (2003)  67 diabetic (Caucasian) 
20 nondiabetic 
21 N 
23 micro 
23 overt 
1. Podocyte density ↓ in all diabetic c/w controls 
2. Podocyte density and filtration slit length density ↓ as AER ↑ 
3. Foot process width ↑ as AER ↑ 
4. Podocyte density may be more relevant than absolute number 
White (2004)  16 diabetic (Caucasian) 
(hypertensive) 
28 nondiabetic 
16 overt 1. Podocyte number ↓ in diabetic c/w controls 
2. Glomerular volume ↑ in diabetic c/w controls 
3. Negative correlation between proteinuria and podocyte number 
and podocyte density per glomerulus 
4. Longitudinal studies are required to determine sequence of events 
   leading to podocyte loss 
 
DN, diabetic nephropathy; N, normoalbuminuria; Micro, microalbuminuria; AER, albumin excretion rate; c/w, compared with. 
                                                                        from: George Jerums, Podocytes and Diabetic Nephropathy, 2006
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Subsequently, two studies were performed in Caucasian patients with type 2 diabetes. 
In the first, a group of 67 patients with an approximately equal proportion of normo-, 
micro-, and macroalbuminuric subjects was studied (52). Podocyte density was 
decreased in all diabetic patients regardless of albuminuria status compared with 
controls. Podocyte density and filtration slit length density decreased as albuminuria 
increased and foot process width increased as albuminuria increased. It was 
concluded that podocyte density may be more relevant to nephropathy than absolute 
podocyte number. A second study in 16 hypertensive Caucasian diabetic patients with 
overt nephropathy was performed recently (53). This showed that podocyte number 
was decreased whereas glomerular volume was increased in diabetic subjects 
compared with controls. There was a negative correlation between proteinuria and 
podocyte number and between proteinuria and podocyte density per glomerulus. As 
in their previous study in type 1 patients, these authors raised the possibility that 
podocyte loss may be part of the disease process rather than a causal factor. This 
would be consistent with the concept that albuminuria is a marker but not the culprit in 
the progression of renal disease (54). The mechanism underlying podocyte loss 
during disaese progression remain incomplelety understood, but may be linked to 
apoptosis or complement activation.  
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1.3.3 Complement and diabetic nephropathy 
Recent evidence suggests that excess complement activation contributes to the 
establishment of diabetic nephropathy (55). The complement system is part of the 
innate immune system, consisting of an enzyme cascade that is activated by one of 
three different pathways (the classical complement, alternative, and mannose-binding 
lectin (MBL) pathways) (56; 57). These three pathways converge, forming the 
protease C3-convertase, which generates C3a and C3b and leads to the formation of 
the membrane attack complex (MAC). Owing to its pro-inflammatory and cell-death 
promoting properties the complement system requires tight regulation. Among the 
negative regulators of complement activation are three membrane proteins, CD46, 
CD55, and CD59, which protect self-cells from complement, either by inhibiting 
complement activation (CD46, CD55) or by regulating MAC assembly (CD59). 
In patients with type 1 and type 2 diabetes mellitus high serum levels of MBL and 
high-coding MBL genotypes are associated with the presence and development of 
microalbumiuria and diabetic nephropathy (36; 58-60). Impairment of complement 
inhibitors may contribute to complement activation and renal damage in diabetes 
mellitus. In vitro high glucose concentrations induce loss of cell surface CD55 and 
CD59 and inactivation of CD59 via glycation (61-63). These data support a role of the 
complement system in diabetic nephropathy. Of note, CD55 and CD59 are expressed 
on endothelial cells and are thus directly exposed to high blood glucose 
concentrations.  
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Given the function of endothelial TM as a complement regulator and the potential role 
of complement in diabetic nephropathy we hypothesized that endothelial TM 
modulates diabetic nephropathy not only through generation of cytoprotective aPC, 
but in addition through complement regulation via its lectin like domain. To test this 
hypothesis we induced persistent hyperglycemia in mice lacking the lectin like domain 
of TM (TMLeD/LeD) (27) and analyzed the extent of experimental diabetic nephropathy 
and potential mechanisms involved. We show that TM’s lectin-like domain modulates 
diabetic nephropathy through complement regulation.  
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2. Material and Methods 
2.1 Chemicals and Reagents 
Agarose, Ultra Pure Invitrogen, Karlsruhe, Germany 
Ammonium Hydroxide Sigma-Aldrich, Taufkirchen, Germany 
Antigen Unmasking Solution Vector Labs, Burlingame, CA, USA 
Aprotinin Sigma-Aldrich, Taufkirchen, Germany 
Benzamidine Sigma-Aldrich, Taufkirchen, Germany 
Bovine Serum Albumin (BSA) Promega, Mannheim, Germany 
Bovine Serum Albumin, fraction V Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent Sigma-Aldrich, Taufkirchen, Germany 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
Collagen Sigma-Aldrich, Taufkirchen, Germany 
2´-Deoxynucleoside 5´-triphosphates 
(dNTPs) 
Invitrogen, Karlsruhe, Germany 
 
Diethylpyrocarbonate (DEPC) Roth, Karlsruhe, Germany 
Dimethyl Sulfoxide (DMSO) Roth, Karlsruhe, Germany 
EDTA Sigma-Aldrich, Taufkirchen, Germany 
Eosin Roth, Karlsruhe, Germany 
Ethanol Sigma-Aldrich, Taufkirchen, Germany 
Ethidium Bromide Sigma-Aldrich, Taufkirchen, Germany 
Formalin, 4% Buffered Roth, Karlsruhe, Germany 
Gelatin from Bovine Skin Sigma-Aldrich, Taufkirchen, Germany 
D-Glucose Sigma-Aldrich, Taufkirchen, Germany 
Glycerol Sigma-Aldrich, Taufkirchen, Germany 
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Hematoxylin, Gill’s Formula Roth, Karlsruhe, Germany 
HOECHST 33258 Sigma-Aldrich, Taufkirchen, Germany 
Hydrogen Peroxide Sigma-Aldrich, Taufkirchen, Germany 
Isoamylalcohol Becton Dickinson, Heidelberg, 
Germany 
Isopropanol Becton Dickinson, Heidelberg, 
Germany 
Kcl (potassium chloride) Roth, Karlsruhe, Germany 
Ladder, DNA, 100bp Promega, Mannheim, Germany 
Leupeptin Sigma-Aldrich, Taufkirchen, Germany 
Magnesium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Mannitol Sigma-Aldrich, Taufkirchen, Germany 
MassRuler, DNA Ladder, Low Range Fermentas, St. Leon-Rot, Germany 
 
2-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Methanol Roth, Karlsruhe, Germany 
Milk Powder Roth, Karlsruhe, Germany 
Nacl (sodium chloride) Sigma-Aldrich, Taufkirchen, Germany 
Na-deoxycholate Sigma-Aldrich, Taufkirchen, Germany 
Na-fluoride Sigma-Aldrich, Taufkirchen, Germany 
Na-orthovanidate Sigma-Aldrich, Taufkirchen, Germany 
Nonidet-p40 (NP-40) Sigma-Aldrich, Taufkirchen, Germany 
Protein Ladder (kDa) Fermentas, St. Leon-Rot, Germany 
Phenol Roth, Karlsruhe, Germany 
PMSF Sigma-Aldrich, Taufkirchen, Germany 
Proteinase K Sigma-Aldrich, Taufkirchen, Germany 
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Protein A/G agarose beads Santa Cruz Biotechnology, 
Heidelberg, Germany 
Roti Histo-Kitt II Roth, Karlsruhe, Germany 
Schiff’s reagent Sigma-Aldrich, Taufkirchen, Germany 
Sheath Fluid, BD FACS Flow Becton Dickinson, Heidelberg, 
Germany 
Sodium Acetate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich, Taufkirchen, Germany 
Streptozocin Sigma-Aldrich, Taufkirchen, Germany 
TEMED Sigma-Aldrich, Taufkirchen, Germany 
Tween-20 Roth, Karlsruhe, Germany 
Tissue Tek, O.C.T. Compound Sakura, Zoeterwonde, The 
Netherlands 
Tris-HCL Sigma-Aldrich, Taufkirchen, Germany 
TRIZOL Invitrogen, Karlsruhe, Germany 
Vectashield Vector Labs, Burlingame, CA, USA 
Xylol Becton Dickinson, Heidelberg, 
Germany 
 
2.2 Proteins, inhibitors and Peptides 
aPC, Recombinant Human, 
Drotrecogin Alpha, Xigris 
Eli Lilly Export S.A., Geneva, 
Switzerland 
ARIXTRA,(fondaparinux sodium) 
Solution for Subcutaneous Injection 
Organon, Sanofi-Synthelabo, USA 
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Levolox (Enoxaparin), Low Molecular 
Weight Heparin, Unfractionated 
Porcine Heparin 
Braun Melsungen AG, Melsungen, 
Germany 
Interferon gamma (IFγ) Cell Sciences, Canton, MA 
Human Protein C Calbiochem, Schwalbach, Germany 
Refludan (Hirudin) Pharmion, Summit, NJ, USA 
Minocycline hydrochloride Sigma-Aldrich, Taufkirchen, Germany 
(U0126) MEK1/2 inhibitor New England biolabs, Frankfurt, 
Germany 
Thrombin, Human, Plasma Purified Sigma-Aldrich, Taufkirchen, Germany 
Human PAR-1 Agonist 
TFLLRNPNDK-NH2 
Biosyntan, Berlin, Germany 
Human PAR-2 Agonist SLIGRL-NH2 Biosyntan, Berlin, Germany 
Human PAR-3 Agonist TFRGAP-OH Bachem, Weil am Rhein, Germany 
Human PAR-4 Agonist AYPGKF-NH2 Sigma-Aldrich, Taufkirchen, Germany 
Control Peptide FSLLRN-NH2 (SCR) Biosyntan, Berlin, Germany 
 
 
2.3 Antibodies and Serum 
Antibody Company Dilution or 
Concentration 
rabbit polyclonal antibody to 
Wilms' tumor-1 (C-19) 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:50 IHC 
rabbit polyclonal antibody to Santa Cruz 1:50 IHC 
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synaptopodin (H-140) Biotechnology, 
Heidelberg, Germany 
rabbit polyclonal antibody to 
GLEPP1 (H-280) 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:50 IHC 
1:400 WB 
Mouse monoclonal anti-human 
PAR3 
(blocking) 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:200 
(20 µg/ml for blocking 
studies) 
Rabbit polyclonal anti-mouse 
Bax 
New England biolabs, 
Frankfurt, Germany 
1:1000 
Rabbit polyclonal anti-mouse 
Bcl2 
New England biolabs, 
Frankfurt, Germany 
1:1000 
Mouse monoclonal anti-human 
Bcl2 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:200 
Mouse monoclonal anti-mouse 
P53 
New England biolabs, 
Frankfurt, Germany 
1:1000 
goat polyclonal antibody to 
complement factor C3 
Cappel, Ohio, USA 1:50 IHC 
1:400 WB 
FITC labelled goat polyclonal 
antibody to complement factor 
C3 
Cappel, Ohio, USA 1:50 IHC 
1:100 FACS 
Rabbit polyclonal beta-actin New England biolabs, 
Frankfurt, Germany 
1:1000 
Rabbit monoclonal anti-mouse 
pERK1/2 
New England biolabs, 
Frankfurt, Germany 
1:2000 
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Rabbit polyclonal 
anti-mouse/human ERK1/2 
New England biolabs, 
Frankfurt, Germany 
1:1000 
mouse monoclonal antibody to 
TGFβ1(ab64715) 
Abcam, Cambridgeshire, 
UK 
1:1000 
rabbit polyclonal antibody to 
VEGF(ab9953) 
Abcam, Cambridgeshire, 
UK 
1:1000 
rabbit polyclonal antibody to 
HMGB1(ab18256) 
Abcam, Cambridgeshire, 
UK 
1:1000 
Rabbit polyclonal anti-mouse 
WT1 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:200 
Rabbit polyclonal anti-mouse 
Nephrin 
Abcam, Cambridge, UK 1:1000 
Phalloidin-FITC conjugated Sigma-Aldrich, 
Taufkirchen, Germany 
50 µg/ml 
Anti-mouse IgG- HRP Abcam, Cambridgeshire, 
UK 
1:5000 
Ant-rabbit IgG- HRP New England biolabs, 
Frankfurt, Germany 
1:2000 
Goat Anti-Rabbit IgG-HRP  Jackson Immuno 
Research, Suttolk, UK 
4 µg/ml 
Fluorescein-goat Anti-mouse 
IgG 
Vector Labs, 
Burlingame, CA, USA 
1:100 
Rabbit Serum, Normal Vector Labs, 
Burlingame, CA, USA 
10% Blocking  
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Goat Serum, Normal Vector Labs, 
Burlingame, CA, USA 
10% Blocking 
 
2.4 Cells 
SVEC4-10 ATCC, Manassas, VA, USA 
Immortalized Human podocytes Obtained from Dr. V. Schwenger 
(Nephrology center, University of 
Heidelberg) 
Immortalized Mouse podocytes Obtained from Dr.Jun Oh (Dept of 
Pediatric Nephrology, University of 
Heidelberg) 
Mouse mesangial cells ATCC, Manassas, VA, USA 
 
 
2.5 Media, Sera, Buffers and Supplements 
DMEM with L-glutamine ATCC, Manassas, VA, USA 
Growth Factors and Supplements 
(FCS, EGF, bFGF, 
Hydrocortisone, Gentamicin 
Sulphate, Amphotericin B) 
PromoCell, Heidelberg, Germany 
 
RMPI-1640 Medium Sigma-Aldrich, Taufkirchen, Germany 
Foetal Bovine Serum Standard 
Quality, EU approved 
PAA laboratories, Pasching, Austria 
Foetal calf Serum Standard 
Quality, EU approved 
PAA laboratories, Pasching, Austria 
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ITS (insulin-transferin-selenium) Sigma-Aldrich, Taufkirchen, Germany 
1x Dulbecco's PBS without Ca and 
Mg 
PAA laboratories, Pasching, Austria 
1x HBSS without Ca and Mg PAA laboratories, Pasching, Austria 
100x Penicillin / Streptomycin PAA laboratories, Pasching, Austria 
0.05 % Trypsin and 0.02 % EDTA PAA laboratories, Pasching, Austria 
 
2.6 Mouse Models 
 
C57BL/6 Charles River Laboratories, Inc., 
Wilmington, MA, USA 
TMLeD/LeD Generous gift from Prof. Dr. EM. Conway, 
UBC Centre for Blood Research, Director, 
Life Sciences Centre Vancouver, BC, 
Canada 
  
2.7 Buffers and Solutions 
2.7.1 Total cell lysate  
RIPA Buffer (final concentration) for whole cell and tissue lysates 
• Tris-HCl: 50 mM, pH 7.4  
• NP-40: 1%  
• Na-deoxycholate: 0.25%  
• NaCl: 150 mM  
• EDTA: 1 mM  
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• PMSF: 1 mM  
• Aprotinin, Leupeptin, Benzamidine: 1 microgram/ml each  
• Na3VO4: 1 mM  
• NaF: 1 mM 
Note: Use RIPA buffer with 0.5% Na-deoxycholate for isolation of proteins from 
tissue. 
 
2.7.2 Nuclear Cell lysates 
Buffer A: Cytoplasmic Fraction                            
KCl   10mM  
Hepes pH 7.6  10mM  
NaVO3   0.1mM 
EDTA   0.1mM 
EGTA   0.1mM 
DTT   0.1m 
NP40   10% 
Protease inhibitors (as mentioned above for RIPA buffer) 
 
Buffer B: Nuclear Fraction               
NaCl           420mM 
Hepes pH 7.6      20mM 
Glycerol 25% 
NaVO3 0.1mM 
EDTA 0.1mM 
EGTA 0.1mM 
DTT 0.1mM 
Protease inhibitors (as mentioned above for RIPA buffer) 
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2.7.3 Buffers for SDS-PAGE 
Electrophoresis resolving-buffer: 
90.825 g (1.5 M) Tris-HCL 
20 ml      (0.4 %) 10 % SDS 
Adjust pH – 8.8  
Make upto 500 ml with dH20 
 
Stacking-buffer: 
30.275 g (1 M) Tris-HCL 
8 ml        (0.4 %) SDS 
Adjust pH – 6.8 
Make upto 200 ml with dH20 
 
Ammoniumpersulfate: 
10 % in dH20 
0.1 g in 1 ml dH20 
 
1 x SDS Sample-buffer 
62.5 mM Tris-HCl (pH 6.8 at 25 0C) 
2 % w/v SDS 
10 % Glycerol 
50 mM DTT 
0.01 % bromophenol blue 
  
5 x SDS Running-buffer: 
30.2 g (0.125 M) Tris                
188 g (1.250 M) Glycine                                  
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100 ml 10 % SDS                                    
Make upto 2 litres with   dH20 
              
Blot-buffer:  
12.125 g (0.02 M) Tris                  
56.250 g (0.15 M) Glycine                            
1000 ml Methanol                                 
Make upto 5 litres with dH20 
 
Blocking buffer:  
PBS-T and TBS-T 
5 g Non-fat dried milk powder 
0.1 % or 0.05 % (v/v) Tween 20  
100 ml 1x PBS or TBS 
 
2.8 PCR Primer Pairs for RT-PCR  
The following primers were purchased from Thermo Electron GmbH, Ulm, Germany 
Annealing Temperature: 68°C; Cycles: 35 
mTM-f 5’ TGCTTCTGCTATGA GGCTATGAGTT 3’  
mTM-r 5’ GGGGTCACAGTCTTTGCTAATCTG A 3’ 
 
Annealing Temperature: 67°C; Cycles: 20 
mβ-actin-f 5' CCGTAAAGACCTCTATGCCAACA 3' 
mβ-actin-r 5' CGGACTCATCGTACTCCTGCT 3' 
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2.9 Kits 
Albumin ELISA kit Bethyl Laboratories, Inc, Montgomery, 
Texas, USA) 
BCA reagent Pierce, Germany 
DAB Substrate Kit for Peroxidase Vector Labs, Burlingame, CA, USA 
ECL reagent (enhanced 
chemiluminiscence) 
Amersham Biosciences, Buckinghamshire, 
UK 
In Situ Cell Death Detection Kit, 
Fluorescein and POD (TUNEL) 
Roche Diagnostics, Mannheim, Germany 
MOM kit Vector Labs, Burlingame, CA, USA 
TAT Elisa Kit Simens Health Care 
Superscript II Reverse 
Transcriptase Kit 
Invitrogen, Karlsruhe, Germany 
 
2.10 Equipment 
ACCU-CHEK Glucose Sticks Roche Diagnostics, Mannheim, Germany 
Accutrent Glucometer Roche Diagnostics, Mannheim, Germany 
BD Chamber Slides for cell culture Becton Dickinson, Heidelberg, Germany 
BD FACS Scan flow cytometer Becton Dickinson, Heidelberg, Germany 
BioDoc Station Biometra, Goettingen, Germany 
Blot chamber Trans-Blot Electrophoretic Transfer Cell,  
Biorad Laboratories, Germany 
Cell culture flasks and dishes Becton Dickinson, Heidelberg, Germany 
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Cell F Imaging Software Olympus, Hamburg, Germany 
Cover slips for cell culture Paul Marienfeld GMBH & Co.KG, 
Lauda-Königshofen, Germany 
Developer (for western blot) CURIX 60, Agfa 
Immobilon-P Transfer Membrane Millipore Corporation, Billerica, MA 
Power supply unit Biorad Laboratories, Germany 
Pipettes Gilson Pipetman, Gilson, Germany 
Pipettes, pipette tips and falcon 
tubes 
Sarstedt, Germany 
Spectrophotometer BIO-TEK-Instruments, Inc, Vermont, USA 
Spectrofluorimeter BIO-TEK-Instruments, Inc, Vermont, USA 
Olympus Ax70 Microscope Olympus, Hamburg, Germany 
T3000 Thermocycler Biometra, Goettingen, Germany 
Hettich-Table Centrifuge GMI, Inc, Minnesota, USA 
Centrifuge-labofuge-400R Heraeus, M & S laborgeräte GMBH, 
Wiesloch, Germany 
High speed ultracentrifuge Beckman Coulter GMBH, Krefeld, Germany 
X-ray film Amersham Biosciences, UK 
 
2.11 Induction of diabetes using streptozotocin 
Diabetes was induced by intraperitoneal administration of streptozotocin (STZ) at 60 
mg/kg, freshly dissolved in 0.05 M sterile sodium citrate, pH 4.5, on 5 subsequent 
days in eight week old mice. Mice were considered diabetic if blood glucose levels 
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were larger 300 mg/dl 16–25 days after the last STZ injection. Blood glucose levels 
were determined in samples from the tail vein using ACCU-CHEK glucose sticks. In 
the first 2 weeks after onset of diabetes, blood glucose was measured daily. If glucose 
levels occasionally recovered, an additional STZ injection was given on days 25–27. 
On average 90% of mice became diabetic (blood glucose > 300 mg/dl) within the first 
4 weeks and were used throughout the experiments. Mice not developing diabetes 
and maintaining blood glucose levels < 200 mg/dl were included in the control group. 
Mice with blood glucose levels between 200 and 300 mg/dl were excluded. Further 
control mice were injected with sodium citrate, pH 4.5 only. Mice displaying blood 
glucose levels above 500 mg/dl received individual supplementation with 1–2 U 
Insulin Semilente. After blood glucose levels had stabilized, blood glucose was 
determined at least once a week. Only mice with blood glucose levels consistently 
larger than 300 mg/dl were used in the diabetes groups. Additional groups of diabetic 
mice we treated with enoxaparin, a low molecular weight heparin , or fondaparinux , a 
FXa inhitor or minocycline, a semisynthetic tetracycline, inhibiting the release of 
cytochrome c from mitochondria and caspase-1, capase-3 and iNOS transcriptional 
up-regulation and activation. Blood samples and tissue samples were obtained after 
26 weeks of persistent hyperglycemia in diabetic mice. Control samples were 
obtained from age matched littermates. At time of analysis the mouse weight and 
weight of organs was recorded. 
2.12 Determination of Albuminuria 
Shortly before sacrificing individual mice were placed in metabolic cages and 
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twenty-four hour urine samples were collected. Urine albumin was determined using 
the mouse albumin ELISA according to the manufacturer’s instructions. Urine 
creatinine was determined using the Jaffé method. 
 
2.13 Histology and immunohistochemistry  
Animals were perfused with ice-cold PBS followed by perfusion with 4% buffered 
Para formaldehyde. Tissues were further fixed in 4% buffered Para formaldehyde for 
2 days, paraffin embedded, and processed for sectioning. TUNEL assays on tissue 
sections were done according to the manufacturer’s instructions. The frequency of 
apoptotic cells was determined by a blinded investigator by counting TUNEL positive 
cells and total cell number within a glomeruli and calculating the percentage of 
TUNEL positive cells. Podocyte numbers were determined by counting WT-1 positive 
cells within glomeruli, atleast 50 glomeruli were counted from each sample.  For 
morphological analyses at least 7 different mice per group with at least 50 glomeruli 
each were included.  
2.14 RT-PCR 
RNA was isolated using TRIZOL reagent from tissue samples stored in RNA-later 
immediately after prepping. cDNA was generated using 1 μg total RNA following 
treatment with DNAse in the concentration 5U/5µg RNA followed by reverse 
transcription using Superscript II. The PCR products were separated on a 1.8% 
agarose gels and visualized by ethidium bromide staining. Expression was 
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normalized to β-actin. Reactions lacking reverse transcriptase served as controls. 
2.15 Cell culture 
All experiments performed with mouse vascular endothelial cells (SVEC4-10) were 
done with passages 4 to 10. Cells were grown on 0.2% gelatin coated plates and 
maintained at 37 oC in a humidified 5% CO2 incubator using endothelial growth 
medium in the presence of growth factors and supplements. Cells were subcultered 
at confluence by trypsinization with 0.05% trypsin and 0.02% EDTA and medium 
changed every other day. All in vitro experiments, except those where thrombin was 
added, were performed in the presence of hirudin (1µg/ml).  
Conditionally immortalized mouse wild-type podocytes were cultures as described 
elsewhere(64; 65). In brief, podocytes were routinely grown on collagen type 1 at 33 
oC in the presence of interferon γ (10 U/ml) to enhance expression of a 
thermosensitive T antigen. Under these conditions, cells proliferate and are 
undifferentiated. To induce differentiation, podocytes were grown at 37 oC in the 
absence of interferon γ for 14 days. We performed experiments 14 days after 
induction of differentiation. Differentiation was confirmed by determining expression of 
Synaptopodin and Wilms´ tumor-1 protein.   
2.16 Protein C activation assay in vivo 
Mice were anesthetized and human PC (20 µg in 100 µl 1xPBS) or 1xPBS (100 µl) 
per mouse were injected via the tail vein. After 10 min blood samples were collected 
from the vena cava into 0.38% sodium citrate and 50 mM benzamidine HCl (final 
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concentrations). Human aPC was captured from these plasma samples using an 
antibody highly specific for human aPC (HaPC 1555), and the activity of the captured 
human protein C was determined using the chromogenic substrate 
SPECTROZYME® PCa as described elsewhere (16). 
 
2.17 Immunoblotting 
Tissue homogenates were prepared using the RIPA buffer containing 50 mM Tris 
(pH7.4), 1% NP-40, 0.5% sodium-deoxycholate, 150 mM Nacl, 1 mM EDTA, 1 mM 
Na3VO4, 1 mM NaF supplemented with protease inhibitor cocktail (from Roche). 
Supernatants were quantified and equal amount of protein samples were 
electrophoretically separated on 10% or 12.5% SDS polyacrylamide gel, transferred 
to PVDF membranes (Millipore) and probed with desired primary antibodies. The 
membrane was then washed with TBST and incubated with α-mouse IgG (1:5000) or 
α-rabbit IgG (1:2000) horseradish peroxidase conjugated antibody. Blots were 
developed with the enhanced chemiluminiscence system (Amersham Piscataway, 
NJ, USA). To compare and quantify levels of proteins, the density of each band was 
measured by densitometer (Biorad). Equal loading was confirmed by staining with 
coomassie brilliant blue -R (CBB) and by actin-western blot.  
 
2.18  Subcellular fractionation 
For determination of Bax-translocation into mitochondria the cytosolic and 
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membranous fractions were isolated as described previously (67). Cells were washed 
in PBS and scraped into isotonic buffer (200 mM mannitol, 70 mM sucrose, 1 mM 
EDTA, 10 mM HEPES-NaOH (ph-7.4), 1 mM DTT, protease inhibitors (as mentioned 
above) and homogenized with a potter Elvehjem homogenizer. Nuclei and unbroken 
cells were removed by centrifugation at 500 g for 10 min at 4oC. The supernatant was 
centrifuged again at 100,000 g for 60 min, and the supernatant was saved as the 
cytosolic fraction. The pellet was washed again in isotonic buffer (15000 x g, for 5 min 
at 4oC), re-suspended in extraction buffer (20 mM HEPES; ph-7.4, 250 mM Nacl, 1 % 
NP-40, 1 mM DTT, 2 mM EDTA, 2 mM Sodium orthovanadate, Protease inhibitors (as 
mentioned above) and centrifuged at 20,000 g for 5 min to remove debris. Samples 
were subsequently used for Western Blotting as described.  
For isolation of cytoplasmic and nuclear extracts from tissues, tissues were 
homogenized in buffer containing 10 mM HEPES, pH 7.9, 10 mM KCL, 1.5 mM 
MgCl2, and 0.5 mM dithiothreitol. After incubation at 4oC for 15 min, the lysates were 
vortexed briefly, centrifuged for 30 s in a microcentrifuge, and the supernatant 
(cytoplasmic fraction) was removed and frozen. The pellet, which contained nuclei 
was resuspended in extraction buffer containing 100 µl of 20 mM HEPES, pH 7.9, 
20% v/v glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM 
phenylmethanesulfonyl fluoride, incubated at 4oC for 30 min. The nuclear extracts 
were then centrifuged at 14000 rpm for 20 min at 4oC. The supernatant was collected 
and stored at -80 oC. Protein concentration was measured using Bradford reagent or 
BCA reagent (Pierce, Germany). 
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2.19 Isolation and culture of primary mouse podocytes 
 
Mouse primary cultured podocytes from out growths of isolated glomeruli were 
prepared essentially as described previously (68). Briefly, glomeruli were isolated 
from wild type and TMLed/Led mice (male, 8 weeks old) under sterile conditions by 
differential sieving of cortical tissue with decreasing pore sizes (200 µM, 150 µM, 100 
µM and 70 µM). After the final wash the isolated mouse glomeruli (purity >95%) were 
resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum and 
ITS solution (Sigma).  For outgrowth of podocytes, isolated whole glomeruli were 
placed on 0.2% collagen (Sigma) coated 6 well plates and maintained at 37 oC in a 
humidified 5% CO2 incubator.  When cells reached confluence, they were removed 
with 0.025% trypsin-0.5 mM EDTA and subcultured in collagen coated 6 well plates at 
1:4 dilutions. The cells showed typical podocyte morphology and positive 
immunocytochemical staining of synaptopodin. 
 
2.20  In vitro analyses of complement activation 
For in vitro analyses of complement activation we used either SVEC4-10 cells, which 
do not endogenously express TM, or primary mouse podocytes isolated from 
TMLeD/LeD or TMwt/wt mice. Cells were cultured as described above, but mouse serum 
was used for the experiments. A subset of cells was incubated for 48 h with high 
glucose concentrations (30 mM final concentration), SVEC4-10 cells were trypsinized 
and resuspend in 1xPBS, Following 30 min incubation with 10% mouse (sources of 
complement) at 37 °C in the presence or absence enoxaparin (55 mg/ml), or 
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fondaparinux (12,5 mg/ml). Concentrations of anticoagulants for in vitro studies were 
based on calculated peak concentrations from mouse in vivo experiments. We 
incubated the cells with FITC-conjugated goat antibody to C3 (Cappel ICN) and 
analyzed the cells for the presence of surface C3 by flow cytometry (BD FACS scan), 
as described else where (69). Since the number of primary podocytes obtained was 
not sufficient for FACS analyses cells were grown in chamber slides, briefly fixed in 
4% formaldehyde ), washed three times with PBS, incubated with the FITC labelled 
goat anti-C3 antibody (30 min), washed again, and then were counterstained with 
Hoechst 33258 (3.5 μg/ml). The overall C3 staining intensity was determined by a 
blinded investigator scoring C3 positive and total cell number in at least 20 random 
areas with the help of an image analysis software Imagine Pro 5.0. Experiments were 
performed in triplicates.  
 
2.21  Red blood cell hemolysis assay 
The red cell hemolysis assay was conducted employing a well-established protocol 
(70). Briefly, freshly collected and carefully washed (3 times) rabbit red blood cells 
(RBC) were incubated with goat anti-rabbit RBC antiserum (20 min, 37 °C, Cappel, 
Ohio, OH, USA). RBCs were then again washed (3 times) and resuspended at a 
concentration of 1.5 x 108 cells/ml. Human (a) or mouse (b) serum (300µl) with 
different dilution of anticoagulants were then added to 50 µl of antibody incubated 
RBCs in the presence of 0.15 mM Ca2+ and 1 mM Mg2+. For positive control 300 µl 
water and for a negative control 300 µl assay buffer were added. Cells were 
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incubated at 37°C for 60 min, then centrifuged (1800 RPM for 10 minutes), and the 
absorbance (415 nm) in the supernatants was determined within 15 minutes after 
centrifugation. The hemolysis rate was calculated by comparing the sample OD with 
the positive control (100%) after subtracting the value of the negative control. 
2.22 Immunoprecipitation 
Immunoprecipitation of podocyte total cellular proteins was done as mentioned else 
where (71). Total cellular proteins were extracted with PBS containing 25 µM of 
proteosome inhibitor MG132 and complete protease inhibitor mixture and were 
sonicated (set at 10% of maximum speed) for 10 sec followed by 1-min incubation on 
ice. This process was repeated five times. Lysates were combined with 3 µg of 
specific antibody and incubated for 2 h at 40C. Immunoprecipitates were collected 
with with protein A/G agarose beads and washed with PBS containing 25 µM MG132 
and protease inhibitor mixture. Immunoprecipitates were fractionated by SDS-PAGE 
(10%), transferred to membranes, and subjected to Immunoblotting with appropriate 
primary and secondary antibodies.  
 
2.23 Cloning of TMwt and TMLed expression constructs 
The expression construct for wild type TM (TMwt) was generated as follows: mouse 
genomic DNA was used as a template for PCR amplification. The whole intronless 
coding sequence was amplified using the primers mTM 1F (5’- GGC GCG CCG CCA 
CCA TGC TTG GGA TTT TCT TTC -3’) and mTM 1R (5’- GAA TTC TCA GAA CTT 
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CTG CAG CGT CCG -3’) using Phusion® High-Fidelity Tag Polymerase. Cycling 
parameters were as follows: 1 min at 98°C; followed by 35 cycles of 10 seconds at 
98°C, 20 seconds at 68°C, 30 seconds at 72°C, and finally a 10 min extension step at 
72°C. After amplification, 50 µL of the amplimer was electrophoretically separated on 
a 0.8% agarose gel containing 10 µg/ml ethidium bromide and visualized under UV 
transillumination, yielding single 1754bp amplimers. PCR fragments were gel purified 
and subcloned into the mammalian expression vector pcDNA™3.1/V5-His TOPO and 
sequenced on both strands to exclude mutations.  
The lectin-like module within the N-terminal domain of TM was removed by PCR as 
follows: DNA fragments encoding the 1-45 AA peptide and 148-577AA peptide of 
mouse TM were amplified using primers mTM 1F (5’- GGC GCG CCG CCA CCA 
TGC TTG GGA TTT TCT TTC -3’), mTM 2R (5’-GGG CGC TGG AAG GAG GAA 
TTC-3’ ) and mTM 2F (5’- GAA TTC CTC GGC CGG ACC CTT C-3’), mTM 3R (5’- 
CAC GTG TCA GAA CTT CTG CAG CGT CCG -3’), respectively. TMwt construct 
served as a template. Amplimers were purified and subcloned into the mammalian 
expression vector pcDNA™3.1/V5-His TOPO as described above, yielding the 
plasmid pT-TMLed-1 and pT-TMLed-2. The TMLed mutant was obtained by subcloning 
the HindIII/EcoRI fragment encoding the 1-45 AA peptide of mouse TM (isolated from 
pT-TM-1) into HindIII/EcoRI of pT-TM-2. 
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 2.24 Generation of stably transfected TMLed and TMwt expressing SVEC4-10 
cells 
SVEC4-10 cells were cultured in DMEM supplemented with 10% FCS. For in vitro 
transfection cells were grown in 6 well plates and transfected with TM plasmids 
according to the manufacturer’s instructions. Stably transfected cell lines were 
selected in the presence of 0.2 mg/ml G418. After 7–10 days of selection cells were 
subcloned by seeding individual clones into 96 well plates. About 30 clones each 
were isolated and clones with comparative TM expression were selected by 
characterizing protein C activation (a function of TM independent of the lectin like 
domain) (72).  
  
2.25 Statistical analyses 
The data are summarized as the mean ± SEM (standard error of the mean). Statistical 
analysis was performed using Student’s t test or ANOVA (as indicated in the figure 
legend or the text). StatistiXL software (www.statistixl.com) was used for all statistical 
analyses. Statistical significance was accepted at the P < 0.05 level. 
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3. Results 
 
Consistent with our observation in the past (16), aPC protects against  diabetic 
nephropathy via PAR-1 and EPCR, later on we were able to show that low dose 
thrombin is also protective in diabetic nephropathy (21). So far we have addressed 
the role of aPC and thrombin in TM-PC system in diabetic nephropathy, the role of TM 
in diabetic nephropathy still remains largely unknown. In order to elucidate the role of 
TM in diabetic nephropathy, the next we applied a mutant mouse strain which lacks 
the N-terminal lectin like domain.  
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3.1 Diabetic nephropathy is enhanced in diabetic TMLeD/LeD mice 
To evaluate the role of TM’s lectin-like domain in diabetic nephropathy we induced 
persistent hyperglycemia in mice lacking the lectin-like domain (TMLeD/LeD mice) and 
in wild type littermates (TMwt/wt). The mortality of mice following streptozotocin 
injections or during the 26 week follow up did not differ. Likewise, blood glucose levels 
did not differ between TMwt/wt and TMLeD/LeD mice (Figure 3.1a). After 26 weeks of 
hyperglycemia albuminuria was significantly increased in diabetic TMLeD/LeD mice (290 
µg/mg vs. 166 µg/mg, P=0.03, Figure 3.1b), while no difference in albuminuria was 
observed in non-diabetic TMLeD/LeD and TMwt/wt mice (46 µg/mg vs. 49 µg/mg, P=0.51, 
Figure 3.1b).  
Histological analyses of tissue sections obtained from perfusion fixed renal tissues 
showed enhanced accumulation of PAS-positive matrix in diabetic TMLeD/LeD mice 
(mesangial index 17.3% vs. 12.0%, P=0.03, Figure 3.1c-e). Of note, a significant 
increase of the mesangial index was already apparent in non-diabetic TMLeD/LeD mice 
(6.4% vs. 4.0%, P<0.001, Figure 3.1c-e). Similar results were obtained when 
analyzing Masson`s trichrome stained sections (Figure 3.1f-g). As noted above, the 
morphological changes in non-diabetic TMLeD/LeD mice were not associated with 
albuminuria. Furthermore, VEGF and TGFβ1 expression and Smad3 phosphorylation 
(a target of TGFβ1 signalling) did not differ between non-diabetic TMLeD/LeD and 
TMwt/wt mice  (Figure 3.1h-j). However, these markers of diabetic nephropathy were 
increased in diabetic TMLeD/LeD mice in comparison to diabetic TMwt/wt mice (VEGF: 
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239% vs. 179%, P=0.03; TGFβ1: 290% vs. 198%, P=0.01; Smad3 phosphorylation: 
314% vs. 191%, P<0.001, Figure 3.1h-j), which is in agreement with the albuminuria 
data. Thus, the absence of TM’s lectin-like domain aggravates nephropathy in 
diabetic mice.  
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Figure 3.1 Loss of TM’s lectin-like domain aggravates experimental diabetic nephropathy 
a: Blood glucose concentrations in non-diabetic wild-type (TMwt/wt C, n=15) and TMLeD/LeD (TMLeD/LeD C, n=14) 
and diabetic wild-type (TMwt/wt DM, n=12) and TMLeD/LeD (TMLeD/LeD DM, n=12) mice.  
b-j: Albuminuria (b), the mesangial index (c,d,e), expression of VEGF (h) or TGFβ1 (i), and phosphorylated Smad3 
(j) in renal cortex extracts of TMwt/wt or TMLeD/LeD mice without or with diabetes (n≥10 for each group). These 
indices of diabetic nephropathy are significantly increased in diabetic TMLeD/LeD as compared to diabetic TMwt/wt 
mice. Representative images of histological sections (c,d,f), bar graph showing the mesangial index (d; ≥50 
glomeruli of at least 7 different mice), images of immunoblots against VEGF, TGFβ1, and Smad3 (h-j; bottom), and 
bar graph summarizing results of immunoblots (h-j, top; n≥7 per group).  
Scale bar: 20 µm (c, f) 40µm (d); C: non-diabetic control mice, open bars; DM: diabetic mice, black bars; mean 
value ± SEM; : P<0.05, : P<0.01. 
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3.2 TM’s lectin-like domain aggravates diabetic nephropathy independent of 
HMGB-1  
 
The lectin-like domain of TM has been previously documented to mediate 
cytoprotection by scavenging HMGB-1 or by inhibiting apoptosis. Hence we 
evaluated whether the protective properties of the lectin-like domain of TM in diabetic 
nephropathy are related to these functions. Using immunohistochemistry we did not  
 
 
 
Figure 3.2 TM’s lectin-like domain regulates diabetic nephropathy independent of HMGB1 
a,b: Using immunohistochemical staining no difference of tissue HMGB1 is detected in TMwt/wt or TMLeD/LeD mice 
without or with diabetes. Representative images of immunohistochemical stains (a, HMGB1 detected by 
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HRP-DAB reaction, brown; hematoxylin counterstain, blue) and bar graph summarizing results (b, n≥10 for each 
group).  
c,d: Tissue (determined by immunoblotting) and plasma levels (determined by ELISA) of HMGB1 are comparable 
in TMwt/wt or TMLeD/LeD mice without or with diabetes. Bar graph summarizing results (c, d, n≥7 for each group). 
Scale bar: 15 µm (a); C: non-diabetic control mice, open bars; DM: diabetic mice, black bars; mean value ± SEM.  
 
observe increased staining for HMGB-1 in renal glomeruli of diabetic TMLeD/LeD mice 
(score 1.32 vs. 1.15 in non-diabetic TMwt/wt mice, P=0.17, Figure 3.2a, b). Likewise, 
no differences were observed in HMGB-1 protein levels in kidney lysates (Figure 3.2c) 
or in plasma (Figure 3.2d) irrespective of the genotype or the presence or absence of 
diabetes. Furthermore, treatment of diabetic TMLeD/LeD mice with transhinone IIA, 
which attenuates cellular HMGB-1 release and is used in patients with cardiovascular 
diseases (73), had no effect on albuminuria or histological indices of diabetic 
nephropathy in diabetic control or TMLeD/LeD mice (data not shown).  
 
Taken together, TM’s lectin-like domain modulates diabetic nephropathy independent 
of its scavenger function in regard to HMGB-1 and independent of its antiapoptotic 
effect.  
 
3.3 TM’s lectin-like domain aggravates diabetic nephropathy independent of 
apoptosis 
We have previously shown that experimental diabetic nephropathy in mice can be 
ameliorated by inhibiting glomerular apoptosis (16). Since TM’s lectin-like domain 
mediates antiapoptotic effects (1) we next evaluated whether apoptosis contributes 
further to the diabetic nephropathy in diabetic TMLeD/LeD mice. Consistent with 
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previous reports glomerular apoptosis was enhanced in diabetic mice (16), both in 
 
Figure 3.3 TM’s lectin-like domain regulates diabetic nephropathy independent of apoptosis 
a,b: Cleaved caspase-3, immunohistochemically detected, is increased to a similar extent in diabetic TMwt/wt and 
diabetic TMLeD/LeD mice. Representative images (a, cleaved caspase-3 detected by HRP-DAB reaction, brown; 
hematoxylin counterstain, blue). The frequency of cleaved caspase-3-positive cells per 50 glomerular profiles was 
determined (b, n≥10 for each group).  
c,d: Expression of apoptosis regulators in renal cortex extracts. Bar graph (top) and representative immunoblot 
(bottom) showing p53 (c) and Bax (d) expression in renal cortex tissue samples (n≥7 for each group). 
Scale bar: 20 µm (a); C: non-diabetic control mice, open bars; DM: diabetic mice, black bars; mean value ± SEM; 
: P<0.05, : P<0.01. 
 
diabetic TMwt/wt mice and in diabetic TMLeD/LeD mice (Figure 3.3a,b). However, no 
difference in apoptosis was apparent when comparing diabetic TMwt/wt with diabetic 
TMLeD/LeD mice (3.86% vs. 4.34%, P=0.13, Figure 3.3a, b). Likewise, expression of 
p53 or Bax did not differ between diabetic TMwt/wt or TMLeD/LeD mice (188% vs. 157% 
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for p53, P=0.36, 159% vs. 142% for Bax, P=0.41, Figure 3.3c, d). Consistent with 
these findings, a tetracycline derivate (minocycline) which prevents glomerular 
apoptosis in diabetic mice (16) had no effect on indices of diabetic nephropathy in 
diabetic TMLeD/LeD mice (data not shown). 
 
3.4 Enhanced glomerular complement deposition in diabetic TMLeD/LeD mice 
 
To explore whether the role of TM’s lectin-like domain in experimental diabetic 
nephropathy may be related to complement activation we determined renal C3 
complement deposition. C3 complement deposition did not differ between 
non-diabetic TMwt/wt mice and TMLeD/LeD mice (1.0 vs. 1.5, P=0.75, Figure 3.4a-c). In 
diabetic mice C3 deposition was only occasional observed outside of glomeruli and 
did not differ between genotypes (Figure 3.4a). Conversely, glomerular C3 deposition 
was increased in diabetic TMwt/wt and to an even larger extent in diabetic TMLeD/LeD 
mice (5.2 vs. 2.6 in diabetic TMwt/wt mice, P=0.03, Figure 3.4b,c). Tissue levels of the 
C3 40 kDa α-chain fragment, which reflects complement activation, were increased in 
diabetic TMwt/wt mice (165% vs. 100%, P=0.02) and were further elevated in diabetic 
TMLeD/LeD mice (242% vs. 165% in diabetic TMwt/wt mice, P<0.001, Figure 3.4d,e). 
Likewise, C5b-9 formation was augmented in diabetic TMwt/wt mice (161% vs. 100%, 
P=0.01) and to a larger extend in diabetic TMLeD/LeD mice (216% vs. 161% in diabetic 
TMwt/wt mice, P=0.01, Figure 3.4f).  
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Figure 3.4 Enhanced glomerular C3 deposition in diabetic TMLeD/LeD mice 
a-c: Immunohistochemical detection of glomerular C3 deposition in TMwt/wt or TMLeD/LeD mice without or with 
diabetes. Representative images (a and b, C3 detected by HRP-DAB reaction, brown; haematoxylin counterstain, 
blue) and bar graph reflecting glomerular C3 deposition (c), n≥10 for each group.  
d,e: Increased levels of the 40 kDa C3 α-chain fragment in renal cortex extracts of diabetic TMLeD/LeD as compared 
to diabetic TMwt/wt mice. Representative immunoblot (d) and bar graph summarizing results (e; n≥7 for each 
group). 
f: C5b-9 (MAC) deposition is increased in diabetic TMLeD/LeD compared to diabetic TMwt/wt mice; representative 
immunoblot and bar graph summarizing results (n≥10 for each group).  
Scale bar: 40 µm (a), 20 µm (b); C: non-diabetic control mice, open bars; DM: diabetic mice, black bars; mean 
value ± SEM; : P<0.05. 
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Contrasting the differential effect of TM`s lectin like domain on complement activation 
in renal glomeruli of diabetic mice no differences in glomerular apoptosis, as reflected 
by cleaved caspase-3 or expression of apoptosis regulators in renal cortex extracts, 
were observed between non-diabetic or diabetic groups, respectively (Figure 3.3). In 
addition, no differences in HMGB-1 levels were observed (Figure 3.4). Taken together, 
these data suggest that TM’s lectin-like domain regulates diabetic nephropathy by 
modulating complement activity in hyperglycemic mice.  
 
 
3.5 Effect of enoxaparin and fondaparinux on complement activation 
 
  
3.5 Effect of enoxaparin and fondaparinux on complement activation  
Enoxaparin (open bars), but not fondaparinux (black bars) reduces complement activation in human (a) and 
background matched mouse (b) serum samples, as determined by the red cell hemolysis assay.  
 
With human serum samples as complement source, Enoxaparin (open bars) at 
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concentration of 40µg/ml can supress the hemolysis by about 50%, at 200µg/ml even 
further to about 80%, but not fondaparinux (black bars), at concentration of 200µg/ml 
can only suppress about 5% of the hemolysis, which is not significant in compare with 
control group(Figure 3.5a) and by applying background matched mouse serum 
samples we could get the same tendency as determined by the red cell hemolysis 
assay (Figure 3.5b).  
 
3.6 Enoxaparin, but not Fondaparinux, reduces glomerular complement C3 
deposition in diabetic TMLeD/LeD mice 
 
Complement inhibitors specifically for mice, in particular for long term in vivo 
intervention studies, are yet not readily available. To this end we used enoxaparin and 
fondaparinux, two factor Xa inhibitors which differ in their ability to inhibit complement 
(69). As described in the last paragraph, employing the red cell hemolysis assay we 
first confirmed that enoxaparin (at 40 µg/ml or higher), but not fondaparinux (up to 200 
µg/ml), inhibited complement activation (Figure 3.5).  
 
Treatment of diabetic TMLeD/LeD mice with enoxaparin or fondaparinux provided 
comparable anticoagulation (Figure 3.6a). Both treatments had no effect on blood 
glucose levels (Figure 3.6b). Yet, only enoxaparin significantly reduced glomerular C3 
(3.1 vs. 5.1, P=0.003, Figure 3.6c-e) and C5b-9 (150% vs. 242%, P<0.001, Figure 
3.6f) deposition.  
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Figure 3.6 Treatment with enoxaparin, but not with fondaparinux, efficiently prevents glomerular 
complement deposition 
a: Plasma levels of thrombin-anti-thrombin (TAT) complexes, a marker of thrombin activation. Enoxaparin and 
fondaparinux both reduce TAT levels in diabetic TMLeD/LeD mice. 
b: Blood glucose concentrations in diabetic TMLeD/LeD mice without (TMLeD/LeD DM, n=12), with enoxaparin 
(TMLeD/LeD DM+Enox, n=10), or with fondaparinux (TMLeD/LeD DM+Fonda, n=10) treatment. 
c-f: Only enoxaparin efficiently reduces glomerular C3 and C5b-9 (MAC) deposition in diabetic TMLeD/LeD mice. 
Representative images of immunohistochemical staining of C3 (c,d, C3 detected by HRP-DAB reaction, brown; 
haematoxylin counterstain, blue) and of an immunoblot for C5b-9 (MAC, f); bar graphs summarizing results (e,f, 
n≥7 for each group).  
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Scale bar: 40 µm (c) 20 µm (d); DM, black bars: diabetic TMLeD/LeD mice; DM + Enox, grey bars: diabetic TMLeD/LeD 
mice treated with enoxaparin; DM + Fonda, speckled bars: diabetic TMLeD/LeD mice treated with fondaparinux; 
mean value ± SEM; : P<0.05, : P<0.01. 
 
 
 
3.7 Enoxaparin, but not fondaparinux, ameliorates nephropathy in diabetic 
TMLeD/LeD mice 
 
Consistent with the complement deposition data show above (Figure 3.6), Enoxaparin, 
but not fondaparinux markedly reduced the severity of nephropathy in diabetic 
TMLeD/LeD mice.  
 
Albuminuria in (85 µg/mg vs. 249 µg/mg, P<0.001, Figure 3.7a), mesangial index 
(10.4% vs. 14.6%, P=0.002, Figure 3.7 b,c,g), renal cortex expression of VEGF 
(139% vs. 198%, P<0.001, Figure 3.7d) or TGFβ1 (131% vs. 266%, P=0.003, Figure 
3.7e), and Smad3 phosphorylation (225% vs. 286%, P=0.04, Figure 3.7f) were 
significantly reduced in enoxaparin as compared to fondaparinux-treated diabetic 
TMLeD/LeD mice. Similar results were obtained when analyzing Masson`s trichrome 
stained sections (Figure 3.7h-i). These data provide experimental evidence that 
enhanced complement activation aggravates nephropathy in diabetic TMLeD/LeD mice.  
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Figure 3.7 Enoxaparin, but not fondaparinux, ameliorates nephropathy in diabetic TMLeD/LeD mice 
a: Enoxaparin, but not fondaparinux, reduces albuminuria in diabetic TMLeD/LeD mice.  
b-i: Enoxaparin, but not fondaparinux, reduces indices of glomerular injury in diabetic TMLeD/LeD mice. Exemplary 
images of PAS stained renal sections (b) and bar graph reflecting mesangial index (c), immunoblots for VEGF (d, 
bottom), TGFβ1 (e, bottom), and phosphorylated Smad3 (f, bottom), and bar graph summarizing results (d-f, top; 
n≥10 for each group).Lower magnification representative renal PAS staining pictures(g), Exemplary images of 
Masson`s trichrome stained sections(h) and bar graph summarizing results reflecting collagen index (i). 
 
Scale bar: 15 µm (b); DM: diabetic TMLeD/LeD mice, black bars; DM + Enox: diabetic TMLeD/LeD mice treated with 
enoxaparin, grey bars; DM + Fonda: diabetic TMLeD/LeD mice treated with fondaparinux, speckled bars; mean value 
± SEM; : P<0.05, : P<0.01. 
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3.8 The lectin-like domain of thrombomodulin prevents glucose-induced C3 
deposition on endothelial cells and podocytes in vitro 
 
The glomerular filtration barrier consists of endothelial cells and podocytes, which 
both express TM (16) (Figure 3.8a and data not shown). To evaluate the role of TM’s 
lectin-like domain for complement deposition on endothelial cells we used murine 
endothelial cells (SVEC4-10), which lack endogenous TM (74). SVEC4-10 cells 
stably expressing wild-type (TMwt) or lectin-deficient (TMLeD) murine TM were cultured 
in the presence of murine serum and low (5 mM, control) or high (30 mM, HG) 
glucose concentrations. In TMwt SVEC cells incubation with HG had only a minor 
effect on cellular C3 deposition (Figure 3.8b), whereas C5b-9 deposition was slightly, 
but significantly increased (1.7 vs. 1.0 in control TMwt cells, P=0.035, Figure 3.8c). 
Conversely, both C3 (180% vs. 100%, P<0.001, Figure 3.8b) and C5b-9 (3.4 vs. 1.0, 
P<0.001, Figure 3.8c) deposition were markedly increased in HG TMLeD SVEC4-10 
cells. Co-incubation of HG treated TMLeD cells with enoxaparin markedly reduced C3 
(55% vs. 180%, P<0.001, Figure 3.8b) and C5b-9 (1.9 vs. 3.4, P<0.001, Figure 3.8c) 
deposition. Fondaparinux likewise reduced glucose-induced C3 and C5b-9 deposition 
on TMLeD endothelial cells, but – in agreement with previous reports (69; 75) – was 
less efficient than enoxaparin (Figure 3.8b-c).  
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Figure 3.8 TM’s lectin-like domain prevents C3 deposition on endothelial cells and podocytes in vitro 
a: Mouse podocytes express TM; representative RT-PCR image (positive control: mouse placenta). 
b,c: Complement deposition (C3, b, and C5b-9, c) on SVEC4-10 cells expressing either wild type TM (TMwt) or a 
TM mutant lacking the lectin-like domain (TMLeD). In TMwt transfected SVEC4-10 cells cultured using mouse serum 
and treated with high glucose concentrations (30 mM, HG) no increase in C3 and only a minor increase of C5b-9 
deposition is observed, while HG markedly increases C3 and C5b-9 deposition on TMLeD SVEC4-10 cells. No C3 
or C5b-9 deposition is observed in cells exposed to mannitol (30 mM) or to glucose (30 mM) in the presence of 
heat inactivated mouse serum (HG+HIS). Enoxaparin (HG+Enox) more efficiently reduces HG-induced C3 or 
C5b-9 deposition as compared to fondaparinux (HG+Fonda); bar graphs summarizing results of FACS (b) or 
immunohistochemical (c) analyses. 
d-f: C3 or C5b-9 deposition on primary murine podocytes obtained from TMwt/wt and TMLeD/LeD mice. C3 and C5b-9 
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deposition is increased in glucose treated (30 mM, HG) TMwt/wt podocytes, but the increase of C3 and C5b-9 is 
larger in HG TMLeD/LeD podocytes. No C3 or C5b-9 deposition is observed in cells exposed to mannitol (30 mM) or 
to glucose (30 mM) in the presence of heat inactivated mouse serum (HG + HIS). Co-incubation with enoxaparin 
(HG+Enox) reduces C3 and C5b-9 deposition, while fondaparinux (HG+Fonda) has no effect. Immunofluorescent 
analyses (d) using a primary FITC-labelled anti-C3 antibody (green); Hoechst 33258 nuclear counter stain (blue); 
bar graph summarizing scoring results for C3 (e) and for C5b-9 (f). 
Scale bar: 20 µm (d); HG: high glucose; Enox: enoxaparin; Fonda: fondaparinux; TMwt: cells transfected with TMwt 
construct; TMLeD: cells transfected with a TM mutant lacking the lectin-like domain; TMwt/wt: podocytes isolated 
from wild type control mice; TMLeD/LeD: podocytes isolated from TMLeD/LeD mice; : P<0.05, : P<0.01. 
 
We next determined whether TM’s lectin-like domain modulates complement 
deposition on podocytes. We isolated primary podocytes from TMwt/wt and TMLeD/LeD 
mice. In TMwt/wt podocytes HG induced C3 (2.0 vs. 1.0, P=0.005, Figure 3.8d-e) and 
C5b-9 (1.8 vs. 1.0, P<0.001, Figure 3.8f) deposition. Again, C3 (4.8 vs. 1.0, P<0.001, 
Figure 3.8d-e) and C5b-9 (3.6vs. 1.0, P<0.001, Figure 3.8f) deposition were much 
more pronounced in HG TMLeD/LeD podocytes. Glucose-induced C3 and C5b-9 
deposition on podocytes were markedly reduced following co-incubation with 
enoxaparin (2.9 vs. 4.8, P<0.001, and 2.0 vs. 3.6, P<0.001, respectively, Figure 
3.8d-f). Conversely, fondaparinux failed to reduce C3 (4.4 vs. 4.8, P=0.41, Figure 3.8 
c,d) or C5b-9 (3.2 vs. 3.6, P=0.12, Figure 3.8f) deposition on HG TMLeD/LeD podocytes. 
Taken together, TM’s lectin-like domain cell-autonomously inhibits complement 
activation on endothelial cells and podocytes.  
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3.9 The lectin-like domain of TM constrains hyperglycemia induced podocyte 
injury  
 
Considering the efficacy of enoxaparin in preventing complement deposition on 
podocytes in vitro we hypothesized that TM’s lectin-like domain protects against 
complement-dependent podocyte injury in diabetic mice. To test this we evaluated the 
extent of podocyte injury in diabetic TMLeD/LeD mice using podocyte specific markers. 
A slightly, but significantly reduced frequency of glomerular WT-1 (Wilm’s tumor-1) 
positive cells was already apparent in non-diabetic TMLeD/LeD mice (7.7 vs. 8.6 in 
non-diabetic TMwt/wt mice, P=0.002, Figure 3.9 a-b). In diabetic TMLeD/LeD mice the 
frequency of WT-1 positive glomerular cells was markedly reduced (4.8 vs. 7.8 in 
non-diabetic TMLeD/LeD mice, P<0.001, and vs. 6.23 in diabetic TMwt/wt mice, P<0.001, 
Figure 3.9a-b). Likewise, loss of GLEPP1 expression, a podocyte specific protein, 
was more pronounced in diabetic TMLeD/LeD mice as compared to diabetic TMwt/wt mice 
(55% vs. 79%, P=0.005, Figure 3.9c-d). Since C3 deposition partially co-localized 
with podocytes (Figure 3.9e) we determined next whether inhibition of complement 
activation prevented podocyte injury. Indeed, following treatment with enoxaparin 
WT-1 (6.7 vs. 5.3, P<0.001, Figure 3.9a-b) and GLEPP1 (84% vs. 55%, P=0.003, 
P=0.003, Figure 3.9c-d) expression were better preserved than following treatment 
with fondaparinux.  
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Figure 3.9 TM’s lectin-like domain protects against complement mediated podocyte injury in diabetic mice 
a,b: Podocyte frequency, as determined by WT-1immunohistochemical staining, is reduced in diabetic TMwt/wt 
mice and to a larger extent in diabetic TMLeD/LeD mice. Treatment with enoxaparin, but not with fondaparinux, 
reduces podocyte loss. Representative immunohistochemical images (a, WT-1 detected by HRP-DAB reaction, 
brown; hematoxylin counterstain, blue) and bar graph summarizing results (b, n≥10 for each group).  
c,d: Expression of GLEPP1 is reduced in diabetic TMLeD/LeD mice compared to diabetic TMwt/wt mice, as 
determined by immunofluorescence staining (c) and immunoblotting (d). Enoxaparin, but not fondaparinux, 
prevents loss of GLEPP-1 expression. Representative immunohistochemical images (c) and immunoblots (d, 
bottom) and bar graph summarizing results (d, top, n≥10 for each group). Anti-GLEPP1 primary antibody and a 
FITC-labelled secondary antibody (c, green). 
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e: Immunofluorescent images showing partial co-localization (yellow) of C3 (green) with the podocyte specific 
marker synaptopodin (red) in diabetic TMLeD/LeD kidney samples; conventional fluorescence microscopy on paraffin 
section, Hoechst 33258 nuclear counter stain (blue).  
Scale bar: 15 µm (a,c,e); C: non-diabetic control mice, open bars; DM: diabetic mice, black bars; mean value ± 
SEM; : P<0.05, : P<0.01 (ANOVA). 
 
 
 
Taken together, TM’s lectin-like domain ameliorates glomerular and podocyte injuries 
in experimental diabetic nephropathy by regulating complement activation. 
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4. Discussion 
 
A potential pathophysiological role of the complement system in diabetic nephropathy 
is supported by studies demonstrating an association between diabetic nephropathy 
and MBL (mannose-binding lectin, a complement activator) in type 1 diabetic patients 
(58; 60) and enhanced immunohistochemical MAC-staining in glomeruli of diabetic 
patients (62; 76). These clinical studies are further supported by experimental work in 
rodent diabetes models (77-80). In the current study we identify a novel mechanism 
regulating complement activation and glomerular damage in experimental diabetic 
nephropathy. Loss of the lectin-like domain of TM results in glomerular complement 
deposition associated with increased indices of experimental diabetic nephropathy. 
Notably, TM, which is primarily known for its expression on and function in endothelial 
cells, is expressed in podocytes, where it cell-autonomously regulates 
glucose-induced complement activation. Hence, the current study does not only 
identify a new function of endothelial TM in regulating complement activation in 
diabetes, but also reveals a novel cytoprotective function of TM in podocytes.  
 
Previously we demonstrated that TM-dependent PC activation protects glomerular 
cells in hyperglycemic mice (16). To evaluate the role of TM-dependent PC activation 
we used a mouse model with a genetically superimposed PC-activation defect 
(secondary to the TMPro-mutation, Glu404Pro) (81). Based on in vitro 
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structure-function analyses this mutation is expected to similarly impair activation of 
both PC and TAFI (thrombin activatable fibrinolysis inhibitor, also known as plasma 
procarboxypeptidase B), although this has formally not been tested in vivo (5) . 
Activated TAFI catalyzes the removal of the C-terminal basic amino acid residues 
Lysine and Arginine, thus inhibiting fibrinolysis, but also modifies the complement 
factors C3a and C5a (82). However, the aggravation of experimental diabetic 
nephropathy in TMPro/Pro mice must be independent of TAFI-dependent complement 
regulation, as concomitantly increasing circulating levels of aPC is fully sufficient to 
protect TMPro/Pro mice from experimental diabetic nephropathy (16). Conversely, the 
mechanism identified in the current study must be independent of PC-activation, 
since activation of PC is not impaired in TMLeD/LeD mice (27) (and data not shown). 
Taken together, our previous and the current results establish that TM prevents 
diabetic nephropathy and podocyte injury in experimental diabetic nephropathy 
through two independent mechanisms, i.e. activation of PC and inhibition of 
complement.  
 
TM is increasingly being recognized as a regulator of complement activation and 
TM’s importance as a complement regulator has recently been demonstrated in 
patients with atypical hemolytic-uremic syndrome (aHUS) (30). aHUS is one of the 
thrombotic microangiopathies, along with thrombotic thrombocytopenia purpura (TTP) 
and preeclampsia. Of note, all three conditions (aHUS, TTP, preeclampsia) are acute 
and potentially life threatening diseases associated with endothelial dysfunction and 
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renal failure. The current study establishes that – at least in mice – TM´s lectin-like 
domain regulates via complement activation diabetic nephropathy, a chronic vascular 
complication frequently leading to renal failure. Thus, impaired TM-dependent 
complement inhibition does not only contribute to acute and potentially catastrophic 
vascular diseases and renal failure, but is in addition mechanistically linked to chronic 
nephropathy, such as occurs in diabetes.  
 
The current in vitro finding that TM’s lectin-like domain prevents complement 
mediated podocyte injury in a cell-autonomous fashion suggests that TM may not 
only protect against endothelial dysfunction, e.g. in the before mentioned 
microangiopathies or in diabetic nephropathy, but directly protects podocyte function 
via inhibition of complement. This raises the question as to whether expression of TM 
on podocytes and hence outside the vascular compartment regulates complement 
activation – and thus podocyte damage – locally. Some fragments of activated 
complement factors are small enough to cross the glomerular filtration barrier (e.g. 
C3a, C3c, or C3dg) and may then interact with podocyte TM. In this case endothelial 
TM may primarily regulate complement activation within the vascular compartment 
and smaller complement fragments crossing the glomerular filtration barrier may be 
subject to regulation by TM expressed by the podocyte. Inactive complement factors 
are generally too large (e.g. complement factor C5: ~177 kDa, or C6: ~93 kDa) and 
regulation of these complement factors by podocytes may only be relevant following 
an initial injury of the glomerular filtration barrier. The expression of some complement 
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factors by podocytes or mesangial cells raises yet another possibility: podocyte TM 
may lessen glomerular injury by regulation these locally synthesized complement 
factors (83). Interestingly, the current finding that TM is expressed on podocytes 
raises the same question in regard to PC activation: Is PC activation on endothelial 
cells or on podocytes required for podocyte protection? Or is PC expressed by 
podocytes? These mechanistic questions can now be addressed using cell-type 
specific deletion of TM’s lectin-like domain or of TM specifically in podocytes or 
endothelial cells.  
 
Normally, the complement system, part of the innate immune system, is tightly 
regulated to avoid collateral tissue damage. The mechanism of complement 
activation in diabetic patients remains incompletely understood. Hyperglycemia and 
the associated metabolic changes appear to be causally related to complement 
activation, considering the reversibility of glomerular C3 deposition in rodents 
following normalization of blood glucose levels (84). High concentrations of glucose 
decrease endothelial expression of CD59, an endogenous inhibitor of complement 
activation in vitro. Glycation of CD59 attenuates its capacity to inhibit MAC formation 
on host cells (61; 85) and renders erythrocytes from diabetic patients more 
susceptible to MAC-mediated lysis (62; 63).  
 
However, murine CD59 lacks the preferential glycation motif, indicating that murine 
CD59 cannot be inactivated by glycation (61). The current and previous observation 
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of enhanced glomerular complement deposition in diabetic mice appear therefore to 
be independent of CD59, pointing towards additional mechanisms. Hyperglycemia 
induced loss of endothelial TM (16; 86; 87), impairing complement inhibition through 
TM’s lectin-like domain, constitutes such an alternative mechanism. Impairment of 
TM-dependent complement regulation may be of broader relevance for diabetes 
mellitus and associated metabolic alterations, considering (A) that enhanced C5b-9 
deposition has been demonstrated not only in the kidney, but in all principal target 
tissues of diabetic complications (62; 76; 88; 89), and given (B) the role of the 
complement system in modulating obesity, lipids, and energy expenditure (90; 91). 
We acknowledge that the current findings need to be evaluated in future studies, 
including studies of human diabetic nephropathy, given the limitations of murine 
models of diabetic nephropathy. Nevertheless, the therapeutic potential arising from 
the current results, i.e. therapeutic intervention with soluble TM (sTM) or small 
molecules targeting complement activation, may constitute a promising approach for 
the treatment of diabetic complications.  
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5. Conclusion  
 
This study establishes that thrombomodulin ameliorates experimental diabetic 
nephropathy not only via aPC, but in addition by dampening complement inhibition via 
its lectin like domain. Thrombomodulin expressed on endothelial cells and podocytes 
controls glucose induced complement activation. This indicates a new function of TM 
outside the vasculature. Thus, these results identify a new function of 
thrombomodulin in chronic vascular disease such as diabetic microangiopathy and a 
novel pathway regulating complement activation in diabetes mellitus. 
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6. Summary 
 
Recent evidence supports a pathogenic role of the complement system in diabetic 
nephropathy. The mechanism through which complement activation is regulated and 
whether complement activation mediates podocyte loss in diabetic nephropathy 
remains unknown. Hyperglycemia reduces expression of thrombomodulin (TM), a 
transmembrane molecule with anticoagulant and cytoprotective functions. TM’s 
cytoprotective effect depends in part on its lectin like domain, which scavenges 
HMGB-1, a RAGE ligand, and inhibits apoptosis and complement. Here we 
determined the role of TM’s lectin like domain in diabetic nephropathy.  
 
Hyperglycemia was induced in mice lacking TM’s lectin like domain (TMLeD/LeD mice) 
using streptozotocin. Following persistent hyperglycemia for 26 weeks albuminuria 
and markers of diabetic nephropathy were analyzed. The role of apoptosis, HMGB-1, 
or complement activation was determined by immunohistochemical analyses, 
immunoblotting, and intervention studies. In vitro experiments were performed to 
characterize complement regulation through TM’s lectin like domain on endothelial 
cells and podocytes.  
 
Albuminuria and indices of diabetic nephropathy were aggravated in diabetic 
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TMLeD/LeD mice, but this was independent of HMGB-1 or apoptosis. Conversely, C3 
deposition is markedly increased in glomeruli of diabetic TMLeD/LeD mice. Inhibition of 
complement activation (using the low molecular heparin enoxaparin) ameliorated 
indices of diabetic nephropathy. In vitro TM’s lectin like domain cell-autonomously 
prevented glucose induced complement activation on endothelial cells and podocytes, 
the two cellular components of the glomerular basal membrane. Consistently, 
podocyte loss, which was enhanced in diabetic TMLeD/LeD mice, was reduced following 
enoxaparin dependent complement inhibition. 
 
The current study identifies a novel mechanism regulating complement activation on 
endothelial cells and podocytes in diabetic nephropathy. Loss of TM’s lectin like 
domain enhances complement activation, aggravating albuminuria, glomerular 
damage, and podocyte loss.  
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